Letermovir vs Valganciclovir for Prophylaxis of CMV in High-Risk Kidney Transplant Recipients
This randomized clinical trial compares the efficacy and safety of letermovir vs valganciclovir prophylaxis for cytomegalovirus (CMV) disease in CMV-seronegative kidney transplant recipients receiving an organ from a CMV-seronegative donor.